|

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

RECRUITINGN/ASponsored by Ohio State University Comprehensive Cancer Center
Actively Recruiting
PhaseN/A
SponsorOhio State University Comprehensive Cancer Center
Started2026-04-28
Est. completion2027-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07609030

Summary

This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity \[I-CAN\]), delivered before and after treatment with chimeric antigen receptor T-cell therapy, works to improve cognitive and neurological outcomes in patients with multiple myeloma or B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or does not respond to treatment (refractory). Cancer treatment can have significant short and long-term side effects, including cognitive and neurological side effects such as impairments in attention, memory, language, and executive function. The I-CAN program is a form of cognitive training. Cognitive training is a therapeutic approach designed to improve and restore cognitive functioning, based on the brain's ability to reorganize and form new neural connections to accomplish tasks. I-CAN provides five core elements necessary for training the brain to create new neural connections including speed of processing, accuracy of processing, adaptivity, generalizability, and engagement. The I-CAN intervention, when delivered before and after therapy, may help reduce the cognitive side effects of treatment in patients with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients \>= 18 years of age
* Diagnosed with relapsed/refractory multiple myeloma (MM) or B-cell non-Hodgkin lymphoma (B-NHL)
* Expected to receive an Food and Drug administration (FDA)-approved CAR-T cellular treatment
* English literacy

Exclusion Criteria:

* Patients expected to live \< 6 months
* Patients with major medical disorder known to affect cognition, such as stroke, encephalitis, traumatic brain injury, brain surgery
* Confirmed Alzheimer disease or other dementia
* Previous central nervous system (CNS) radiation
* Active intrathecal therapy at time of enrollment

Conditions5

CancerRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Multiple MyelomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Multiple Myeloma

Locations1 site

Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Ashley E. Rosko, MD614-688-7397Ashley.Rosko@osumc.edu

Find trials near these locations

Cancer trials in ColumbusAll trials in Ohio

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.